Form 4: Broadwood Partners Acquires $7 Million Stake in Oncocyte Corp
SEC Form 4
Broadwood Partners, L.P. acquired 2,420,000 shares of Oncocyte Corp common stock in a private placement, while also seeing its Series A Convertible Preferred Stock redeemed by the issuer.
Summary
- Broadwood Partners, L.P. acquired 2,420,000 shares of Oncocyte Corp common stock on April 11, 2024, through a private placement at a price of $2.9164 per share, totaling $7,057,688.
- On April 15, 2024, Oncocyte Corp mandatorily redeemed all 2,941.1765 shares of Series A Convertible Preferred Stock previously held by Broadwood Partners for $3,289,144.18, or $1,118.30902 per share.
- The reported securities reflect Oncocyte's 1-for-20 reverse stock split that took effect on July 24, 2023.
Sentiment
Score: 6
Explanation: The sentiment is neutral. While Broadwood Partners increased its stake in Oncocyte, the redemption of preferred stock suggests a restructuring of the investment. The reverse stock split is a mixed signal, often indicating an attempt to improve stock price but also potentially reflecting underlying financial challenges.
Positives
- Broadwood Partners increased its investment in Oncocyte through the purchase of common stock.
- Broadwood Partners received redemption proceeds for its Series A Convertible Preferred Stock.
Industry Context
This announcement reflects ongoing investment activity in the biotechnology sector, with a specific focus on companies like Oncocyte involved in precision oncology and diagnostics. Private placements and stock redemptions are common financial maneuvers used by companies to manage capital structure and attract investment.
Comparison to Industry Standards
- Private placements are a common method for small to mid-cap biotech companies to raise capital, often at a discount to the current market price.
- Redemption of preferred stock is a standard corporate finance activity to streamline the capital structure.
- Reverse stock splits are often undertaken by companies to increase their stock price to meet exchange listing requirements or to improve investor perception, however, they can also be a sign of financial distress.
Stakeholder Impact
- Shareholders may see changes in the stock price due to the stock purchase and redemption.
- The company's financial structure is impacted by the stock purchase and redemption.
Key Dates
| Date | Description |
|---|---|
| 07/24/2023 | Oncocyte's 1-for-20 reverse stock split became effective. |
| 04/11/2024 | Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte to acquire common stock. |
| 04/11/2024 | Broadwood Partners acquired 2,420,000 shares of Oncocyte Corp common stock. |
| 04/15/2024 | Oncocyte mandatorily redeemed all Series A Convertible Preferred Stock held by Broadwood Partners. |
| 04/15/2024 | Broadwood Partners, Broadwood Capital, and Neal C. Bradsher signed the SEC Form 4. |
| 04/19/2027 | Expiration date of Warrants to Purchase Common Stock |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.